Both PPAR agonists and GLP-1 drugs show promise for treating fatty liver disease in people with type 2 diabetes, through complementary mechanisms.
>50% co-occurrenceMore than half of all people with type 2 diabetes also have non-alcoholic fatty liver disease
What the researchers found
PPAR agonists work by making cells more sensitive to insulin. Pioglitazone (a PPARγ agonist) and saroglitazar (a PPARα/γ agonist) are recommended by several medical groups for treating fatty liver in diabetes. Newer PPAR drugs like elafibranor and lanifibranor are also showing promise.
GLP-1 receptor agonists take a different approach. They produce significant weight loss and may directly reduce liver inflammation and fibrosis (scarring). The review notes that dual-agonists (like tirzepatide targeting GIP/GLP-1) and triple-agonists have produced even more impressive weight loss, which could further benefit the liver. However, direct evidence of liver benefit from these newer multi-agonists is still limited.
Why it matters
NAFLD affects over half of all people with type 2 diabetes, and the combination dramatically increases risk of liver failure, liver cancer, and cardiovascular events. Until resmetirom's recent approval, there was no drug specifically approved for NAFLD. This review shows that existing diabetes drugs may offer liver benefits as a bonus.
The numbers in context
- More than 50% of people with type 2 diabetes have NAFLD
- Pioglitazone: recommended by multiple guidelines for NAFLD in diabetes
- GLP-1 receptor agonists: shown beneficial effects on NAFLD/NASH
- Dual and triple agonists: impressive weight loss, potential liver benefits under investigation
How the study worked
This is a narrative review examining the evidence for PPAR agonists and GLP-1-based therapies in treating NAFLD/NASH in people with type 2 diabetes. It covers both approved drugs and drugs in development, drawing on clinical trial data and mechanistic research.
Who was studied
People with type 2 diabetes and non-alcoholic fatty liver disease
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. It does not quantify effect sizes or grade evidence systematically. Long-term safety data for newer PPAR agonists and multi-agonist GLP-1 drugs in liver disease is lacking. Biopsy-proven NASH data is missing for saroglitazar. The review does not address cost or access barriers.
How to read the evidence
Rated moderate: narrative review of established and emerging evidence, covering guideline-recommended drugs and newer agents with less robust data.
When this study was published
Published in 2024. The landscape is evolving rapidly with resmetirom's recent approval and ongoing trials of tirzepatide for liver disease.
The bigger picture
Fatty liver disease affects over half of all people with type 2 diabetes. Having diabetes drugs that also treat the liver could simplify treatment and reduce the combined cardiovascular and liver risk these patients face.
Questions still open
- Will tirzepatide's dual mechanism provide superior liver benefits?
- Can combining PPAR agonists with GLP-1 drugs produce additive liver benefits?
Common questions
Can a diabetes drug treat fatty liver?
Which diabetes drugs are best for fatty liver?
Read the original research
Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.
World journal of methodology, 14(2), 91319
Citation
Pramanik, Subhodip; Pal, Partha; Ray, Sayantan. (2024). Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.. World journal of methodology, 14(2), 91319. https://doi.org/10.5662/wjm.v14.i2.91319